Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 14 December 2023, 17:02 HKT/SGT
Share:
    

Source: Eisai
Eisai and Mizuho Sign Sustainability-Linked Loan Agreement

Eisai Co., Ltd. and Mizuho Bank, Ltd. announced today that the companies have signed a sustainability-linked syndicated loan agreement, which comes into effect today.

Sustainability-linked loans are a type of loan which incentivizes borrowers to achieve sustainability performance targets (“SPTs”) by linking borrowing terms and conditions, such as interest rates, to the achievement of the SPTs, seeking to drive environmental and socially sustainable economic activities and economic growth.

Under the concept of human health care (hhc), Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. through activities such as innovative drug discovery in the fields of dementia, cancer, and global health. Particularly in the domain of dementia, Eisai has developed “LEQEMBI®”, a new drug for Alzheimer’s disease(AD), which obtained approval in the US and Japan this year. By delivering LEQEMBI to people with early AD around the world, Eisai aims not only to improve their health outcomes but also contribute to address social issues regarding AD, including long term nursing care.

Eisai has set social impact targets for LEQEMBI in the U.S. and Japan based on its social value in terms of its effects on health outcomes and on cost reductions in nursing care and other expenses, and has established these as the SPTs of this agreement. With the funds raised through this agreement, Eisai will promote the creation of social impact through the elimination of diseases of poverty (neglected tropical diseases, malaria, tuberculosis, etc.), in addition to the establishment of programs to offer LEQEMBI to low-income populations for free in the U.S. and emerging countries, and the building of dementia ecosystems.

This agreement has undergone a third-party review* by Rating and Investment Information, Inc. (R&I) regarding its compliance with the Sustainability-Linked Loan Principles issued by the Loan Market Association and other organizations, as well as the Green Loan and Sustainability-Linked Loan Guidelines issued by Japan’s Ministry of the Environment.

Mizuho Bank is committed to the Mizuho group's purpose of “proactively innovate together with our clients for a prosperous and sustainable future”, with the desire to co-create a prosperous future with clients by supporting their endeavors and challenging ourselves. Mizuho’s new medium-term business plan, which began in FY2023, is a three-year journey connecting various initiatives and co-creating value-added solutions in order to support our clients and solve social issues. As part of this, we are seeking out ways to have positive social impacts in areas such as realization of a more inclusive society and improvement in Japan’s global competitiveness.

Mizuho Bank's role in connecting initiatives and creating social impact and outcomes is to support sustainability transformation from multiple angles by working together to find solutions for the development of clients and society from a medium- to long-term perspective.

Mizuho Bank will continue working together with our clients to achieve sustainability transformation by providing sustainable finance that creates a flow of funds to address environmental and social issues, and by providing solutions that utilize knowledge and functions that go beyond finance.

Overview of Loan Terms

Borrower: Eisai
Method: Syndication
Arranger: Mizuho Bank
Lenders: 39 financial institutions
Loan amount: 50 billion yen
Agreement date: December 6, 2023
Drawdown date: December 13, 2023

* Please refer to the opinion provided by Rating and Investment Information, Inc. (R&I).

https://www.r-i.co.jp/en/rating/esg/sustainabilityfinance/index.html

Media Inquiries
Eisai Co., Ltd.
Public Relations Department
+81 (0)3-3817-5120

Mizuho Bank, Ltd
Public Relations Office
+81 (0)3-5252-6574




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: